StarZero All shows Try the podcast clipper →

R&D

3 statements across 1 episodes · 3 bullish · 0 bearish · 1 people on the record · first statement Nov 11, 2025 by Dave Ricks · across every show →

Everything said about R&D, oldest first

Nov 11, 2025 bullish
Assertion Supported
Ricks: Lilly will spend nearly 25% of revenue on R&D this year
“We'll spend almost 25% of sales this year. John Collison: I liked your way of putting us that you spend more on medical R&D than Germany does. Dave Ricks: Yes. Dave Ricks: Yeah. Dave Ricks: We're at the nation state level. It'll be, you know, fourteen billion …”
Dave Ricks Nov 11, 2025 ▶ 8:45 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Nov 11, 2025 bullish
Assertion Supported
Ricks: Lilly R&D spend is growing ~20% while headcount grows single digits
“So we're growing R&D high teens, early low twenties. We're growing headcount in R&D single digits.”
Dave Ricks Nov 11, 2025 ▶ 2:04:28 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Nov 11, 2025 positive
Opinion
Ricks: Lilly's industry-leading R&D ROI comes from process, not picking winners
“I think one of the reasons Lilly has probably the highest return on investment in R&D in the industry is because not the picking of winners and losers, but the, actually the process by which we run it.”
Dave Ricks Nov 11, 2025 ▶ 10:54 Dave Ricks, CEO of Eli Lilly, on GLP-1s and the business of pharma
Made with StarZero

Turn any episode into a week of clips.

This entire site, about 28 episodes transcribed, diarized, checked and made playable, runs on the StarZero media pipeline. Drop in your own episode and the podcast clipper finds the moments worth sharing, cuts them, captions them, and reframes them for every feed.

Try the podcast clipper Learn more